iSCIB1+ (SCIB1)
Advanced Unresectable Melanoma
Phase 2/3Active - Phase 2 ongoing; FDA IND cleared for Phase 3 (Jan 2026)
Key Facts
Indication
Advanced Unresectable Melanoma
Phase
Phase 2/3
Status
Active - Phase 2 ongoing; FDA IND cleared for Phase 3 (Jan 2026)
Company
About Scancell
Scancell's mission is to create a cancer-free future by developing safe, effective, and accessible active immunotherapies. Its core achievement is the advancement of two distinct technology platforms—Immunobody® for DNA vaccines and Moditope® for citrullinated peptide vaccines—into clinical trials, with a lead Phase 3 program in melanoma. The company's strategy focuses on combining its off-the-shelf therapies with standard checkpoint inhibitors to improve outcomes in hard-to-treat cancers, while also exploring earlier-stage antibody assets through its Glymab subsidiary.
View full company profile